Molecule to Medicine and Oktopi announce collaboration to make lean drug development smarter
Molecule to Medicine (MTM) and Oktopi today announced a collaboration to strengthen how drug development decisions are made, combining MTM's lean, efficient operating model with Oktopi's AI-enabled decision infrastructure.
The partnership is built on two shared objectives. The first is to de-risk and drive efficiencies in drug development. The second is to leverage technology and data to inform better decision-making. Rather than replacing expert judgement, the approach is designed to amplify it by surfacing the right questions, evidence and precedent at the point teams are making critical calls.
Oktopi, built by drug developers, provides an expert-curated platform that helps teams interrogate development plans, identify gaps, and make evidence-based go/no-go decisions with human accountability at every step. MTM brings an innovative, capital-efficient model for advancing medicines, a natural fit for a technology designed to make small, expert teams more effective.
Kirsty McCarthy, CEO and Founder, MTM said,
"At MTM, our model is built on doing more with less, advancing medicines through a lean, efficient operating approach. Partnering with Oktopi lets us bring technology and data directly into our decision-making, helping us de-risk development and move with confidence. We're excited to see where this collaboration takes us."
Dr Craig Rayner AM, Oktopi Co-Founder and CEO said,
"What excites us about MTM is the model itself: lean, deliberate and effective. Coupling that with Oktopi's decision infrastructure is a natural fit, bringing technology and data together with experienced developers to make sharper, faster, evidence-based decisions. We're delighted to be partnering with MTM."
The collaboration begins with a pilot, with both organisations planning to share results as the work progresses.
About Molecule to Medicine
Molecule to Medicine (MTM) is a global biotech ecosystem operating across the UK and Australia, dedicated to co-creating, nurturing, and scaling breakthrough therapeutic ventures.
Led by experienced drug hunters, MTM pairs agile operational strategies with advanced bioinformatics to rapidly translate complex biological data into actionable intelligence. This lean, technology-driven approach systematically de-risks development while optimizing capital efficiency. By forging vital connections across science, data, and venture creation, MTM accelerates the path from molecule to medicine, building high-impact lifescience companies and delivering transformative therapies.
About Oktopi
Oktopi is an AI-informed knowledge and workflow engine designed to strengthen decision quality, transparency, and efficiency across the medicine development lifecycle. The platform integrates expert-built taxonomies, logic, and human-guided AI workflows with a growing global community of contributors.
Oktopi helps teams and governance bodies work with greater clarity and consistency, supporting developers of all sizes, including those in LMICs, to operate at globally recognized best practice standards.